[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Duval
X
X
Service des Maladies infectieuses et tropicales, Groupe hospitalier Bichat-Claude-Bernard, Paris.
D000480:Alkynes; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D048588:Benzoxazines; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D000998:Antiviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; C402066:GW420867X; D017320:HIV Protease Inhibitors; D010078:Oxazines; D011810:Quinoxalines; D018894:Reverse Transcriptase Inhibitors; D014498:Uracil; C098320:efavirenz; C083858:emivirine